From the Food and Drug Administration.
Nightingale
S L
SL
D000818:Animals; D002167:Campylobacter / Q000187:drug effects*; D002169:Campylobacter Infections / Q000188:drug therapy / Q000453:epidemiology / Q000662:veterinary; D000697:Central Nervous System Stimulants / Q000008:administration & dosage / Q000627:therapeutic use; D002638:Chewing Gum; D017277:Drug Approval; D004352:Drug Resistance, Microbial; D018432:Drug Resistance, Multiple; D004926:Escherichia coli / Q000187:drug effects*; D004927:Escherichia coli Infections / Q000188:drug therapy / Q000453:epidemiology / Q000662:veterinary; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D009538:Nicotine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004366:Nonprescription Drugs; D011109:Polymethacrylic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D011145:Polyvinyls / Q000008:administration & dosage / Q000627:therapeutic use*; D011159:Population Surveillance; D018357:Respiratory Syncytial Virus Infections / Q000188:drug therapy; D012136:Respiratory Syncytial Viruses / Q000276:immunology*; D012475:Salmonella / Q000187:drug effects*; D012480:Salmonella Infections / Q000188:drug therapy / Q000453:epidemiology; D012481:Salmonella Infections, Animal / Q000188:drug therapy / Q000635:transmission; D016540:Smoking Cessation; D061485:Tobacco Use Cessation Devices; D014481:United States / Q000453:epidemiology; D014486:United States Food and Drug Administration
D000697:Central Nervous System Stimulants; D002638:Chewing Gum; D016756:Immunoglobulins, Intravenous; D004366:Nonprescription Drugs; D011109:Polymethacrylic Acids; D011145:Polyvinyls; C098685:respiratory syncytial virus immune globulin intravenous; D009538:Nicotine